Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline R&D Chairman Moncef Slaoui tasked Sandy Macrae in 2008 to put together a group that would make sure GSK focused some of its R&D efforts on the needs of Asia Pacific and emerging markets. Since then, GSK's APJEM R&D - Asia Pacific, Japan, and Emerging Markets - has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't. Macrae's lean eight-person team has, in its approach to companies, said that while GSK is looking for later-stage molecules, the group is not opposed to licensing a compound for Asia while its partners pursue Western deals with another company (PharmAsia News, April 9, 2009).

You may also be interested in...



Astellas Transfers Compounds To DNDi For Drug Discovery In Chagas, Leishmaniasis and Sleeping Sickness

Astellas and other Japanese pharma have become more open to new partnerships that expand drug access, as well as their market footprint.

Astellas Transfers Compounds To DNDi For Drug Discovery In Chagas, Leishmaniasis and Sleeping Sickness

Astellas and other Japanese pharma have become more open to new partnerships that expand drug access, as well as their market footprint.

PhamAsia News Top Editors' Picks Of 2010

More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel